MCID: SML009
MIFTS: 56

Small Intestine Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Small Intestine Adenocarcinoma

MalaCards integrated aliases for Small Intestine Adenocarcinoma:

Name: Small Intestine Adenocarcinoma 12 15
Small Intestinal Adenocarcinoma 12 52 17
Adenocarcinoma of the Small Instestine 52 58
Adenocarcinoma of the Small Bowel 52 58
Adenocarcinoma of Small Instestine 52
Adenocarcinoma of Small Intestine 12
Adenocarcinoma of Small Bowel 52
Small Bowel Adenocarcinoma 52

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:4906
NCIt 49 C7888
ICD10 via Orphanet 33 D01.4
UMLS via Orphanet 72 C0278803
Orphanet 58 ORPHA104075
UMLS 71 C0278803

Summaries for Small Intestine Adenocarcinoma

NIH Rare Diseases : 52 Small intestine adenocarcinoma is one type of small bowel cancer , usually occurring in the duodenum or jejunum, that begins in the gland cells . The small intestine is part of the body's digestive syste m, which also includes the esophagus, stomach, and large intestine. The exact cause is still unknown, but it may be due to DNA changes in the small intestine adenocarcinoma cells. The symptoms of small bowel tumors are often vague. The most common symptoms are pain in the belly (which may be the first symptom), weight loss, weakness, fatigue and low red blood cell counts (anemia ). The treatment and prognosis for small intestine cancer depends on its stage (tumor size and site) and the presence of metastases . For early stage cancer, surgery may be all that is needed. For more advanced cancer chemotherapy or radiation therapy may be required. Please visit the National Cancer Institute website for additional information: Small Intestine Cancer Treatment (PDQR)-Patient Version

MalaCards based summary : Small Intestine Adenocarcinoma, also known as small intestinal adenocarcinoma, is related to attenuated familial adenomatous polyposis and jejunal adenocarcinoma. An important gene associated with Small Intestine Adenocarcinoma is S100A4 (S100 Calcium Binding Protein A4), and among its related pathways/superpathways are TCR Signaling (Qiagen) and Endometrial cancer. The drugs Oxaliplatin and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include small intestine, colon and liver, and related phenotypes are digestive/alimentary and neoplasm

Disease Ontology : 12 A small intestine carcinoma that derives from epithelial cells of glandular origin.

Related Diseases for Small Intestine Adenocarcinoma

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Small Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 attenuated familial adenomatous polyposis 30.3 MSH6 MSH2
2 jejunal adenocarcinoma 30.3 MSH6 MLH1
3 appendix adenocarcinoma 29.8 KRAS HRAS
4 jejunal cancer 29.6 PMS2 MSH6 MSH2 MLH1
5 adenocarcinoma 29.4 SMAD4 MSH6 MSH2 MLH1 KRAS HRAS
6 ulcerative colitis 29.1 SMAD4 MSH6 MSH2 MLH1
7 signet ring cell adenocarcinoma 28.9 MUC6 MSH2 MLH1 KRAS HRAS
8 duodenum adenocarcinoma 28.8 PMS2 MUC6 MSH6 MSH2 MLH1 KRAS
9 colorectal adenocarcinoma 28.7 PMS2 MSH6 MSH2 MLH1 KRAS HRAS
10 adenoma 28.4 SMAD4 MUC6 MSH6 MSH2 MLH1 KRAS
11 familial adenomatous polyposis 28.0 SMAD4 MSH6 MSH2 MLH1 KRAS HRAS
12 lynch syndrome 27.5 SMAD4 PMS2 MSH6 MSH2 MLH1 KRAS
13 pancreatic cancer 27.5 SMAD4 S100A4 MUC6 MSH2 MLH1 KRAS
14 endometrial cancer 27.5 SMAD4 PMS2 MSH6 MSH2 MLH1 KRAS
15 gastric cancer 27.4 SMAD4 S100A4 MUC6 MSH2 MLH1 KRAS
16 colorectal cancer 26.9 SMAD4 S100A4 PMS2 MUC6 MSH6 MSH2
17 small intestine cancer 26.8 SMAD4 PMS2 MUC6 MSH6 MSH2 MLH1
18 polyposis syndrome, hereditary mixed, 1 10.3 MUC6 MLH1
19 lower lip cancer 10.3 MSH2 MLH1
20 spindle cell intraocular melanoma 10.3 PMS2 MLH1
21 cervical mucinous adenocarcinoma 10.2 MSH6 MSH2
22 anal fistula 10.2 MSH2 MLH1
23 colorectal cancer, hereditary nonpolyposis, type 4 10.2 PMS2 MLH1
24 transverse colon cancer 10.2 MLH1 KRAS
25 deficiency anemia 10.2
26 renal pelvis transitional cell carcinoma 10.2 MSH6 MSH2 MLH1
27 cervical adenoma malignum 10.2 MSH6 MSH2 MLH1
28 autosomal dominant non-syndromic intellectual disability 8 10.2 MSH6 MSH2 MLH1
29 mental retardation, autosomal dominant 20 10.2 MSH6 MSH2 MLH1
30 iron deficiency anemia 10.2
31 ileus 10.2
32 dysplastic nevus syndrome 10.2 MSH6 MSH2 MLH1
33 fallopian tube endometrioid adenocarcinoma 10.1 PMS2 MSH6
34 ectomesenchymoma 10.1 MSH2 HRAS
35 microphthalmia, isolated 3 10.1 HRAS CPS1
36 crohn's disease 10.1
37 rare tumor 10.1
38 rectum signet ring adenocarcinoma 10.1 PMS2 MSH2 MLH1
39 gastrointestinal carcinoma 10.1
40 signet ring basal cell carcinoma 10.1 KRAS HRAS
41 trachea carcinoma in situ 10.1 KRAS HRAS
42 nasal cavity adenocarcinoma 10.1 KRAS HRAS
43 intussusception 10.1
44 tubular adenocarcinoma 10.1
45 ampulla of vater neoplasm 10.1 KRAS HRAS
46 acneiform dermatitis 10.1 KRAS HRAS
47 eccrine papillary adenoma 10.1 KRAS HRAS
48 papillary adenoma 10.1 KRAS HRAS
49 mucinous lung adenocarcinoma 10.0 KRAS HRAS
50 legius syndrome 10.0 MSH6 MSH2

Graphical network of the top 20 diseases related to Small Intestine Adenocarcinoma:



Diseases related to Small Intestine Adenocarcinoma

Symptoms & Phenotypes for Small Intestine Adenocarcinoma

MGI Mouse Phenotypes related to Small Intestine Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 HRAS KRAS MLH1 MSH2 PMS2 SMAD4
2 neoplasm MP:0002006 9.23 HRAS KRAS MLH1 MSH2 MSH6 PMS2

Drugs & Therapeutics for Small Intestine Adenocarcinoma

Drugs for Small Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 6857599 43805
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
4
Ondansetron Approved Phase 3 99614-02-5 4595
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Fluorouracil Approved Phase 3 51-21-8 3385
7 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
8 Cola Phase 3
9 Gastrointestinal Agents Phase 3
10 Antineoplastic Agents, Hormonal Phase 3
11 Liver Extracts Phase 3
12 Antiemetics Phase 3
13 Central Nervous System Depressants Phase 3
14 Neurotransmitter Agents Phase 3
15
protease inhibitors Phase 3
16 BB 1101 Phase 3
17 Anti-Anxiety Agents Phase 3
18 Antipruritics Phase 3
19 Antipsychotic Agents Phase 3
20 Tranquilizing Agents Phase 3
21 Dermatologic Agents Phase 3
22 Hormone Antagonists Phase 3
23 Autonomic Agents Phase 3
24 Anti-Inflammatory Agents Phase 3
25 HIV Protease Inhibitors Phase 3
26 Psychotropic Drugs Phase 3
27 glucocorticoids Phase 3
28 Serotonin Antagonists Phase 3
29 Serotonin Agents Phase 3
30 Hormones Phase 3
31 Narcotics Phase 3
32 Anesthetics Phase 3
33 Anesthetics, General Phase 3
34 Analgesics, Opioid Phase 3
35 Adjuvants, Anesthesia Phase 3
36 Anesthetics, Intravenous Phase 3
37 Analgesics Phase 3
38
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
41
Bevacizumab Approved, Investigational Phase 2 216974-75-3
42
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Floxuridine Approved Phase 2 50-91-9 5790
45
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
46
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
47
Hydroxyurea Approved Phase 2 127-07-1 3657
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
Melphalan Approved Phase 2 148-82-3 4053 460612
50
Acetaminophen Approved Phase 2 103-90-2 1983

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients Completed NCT01180452 Phase 4
3 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
4 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 PRODIGE 33 - BALLAD - Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma Not yet recruiting NCT02502370 Phase 3 observation alone;LV5FU2;FOLFOX
6 A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
7 Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin
8 Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01202409 Phase 2 Panitumumab
9 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
10 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
11 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
12 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
13 A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
14 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
15 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
16 Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine Active, not recruiting NCT03000179 Phase 2 Avelumab
17 A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas Active, not recruiting NCT02949219 Phase 2
18 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
19 Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies Completed NCT00544193 Phase 1 gemcitabine hydrochloride
20 Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
21 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
22 Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies Completed NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
23 A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion in Refractory Advanced Stage Ovarian Cancer and Other Abdominal Carcinomatosis Completed NCT00003439 Phase 1
24 Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas Completed NCT00003046 Phase 1
25 Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
26 A Phase I Clinical Trial To Assess The Safety And Efficacy Of Intraperitoneal PV701 Administrations In Patients With Advanced Or Recurrent Malignancy Largely Confined To The Peritoneal Cavity Completed NCT00055705 Phase 1
27 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
28 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
29 A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
30 A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System Completed NCT00010023 Phase 1 capecitabine;cisplatin
31 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
32 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
33 Prospective Randomized Comparison Between Axial- and Lateral-viewing Capsule Endoscopy Systems in Celiac Patients: a Pilot Study Unknown status NCT03095573
34 A Capsule Endoscopy and Double Balloon Enteroscopy Sequential Approach for Early Detection of Gastrointestinal Tumors in Celiac Disease: a Prospective Trial Unknown status NCT02325232
35 Visceral Lymphatic Mapping Project: A Pilot Study Completed NCT00489515
36 Improving Palliative Care for Patients With Cancer Completed NCT00253383
37 Study of Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma Recruiting NCT03800212 treatment for ampullary adenocarcinoma
38 Phenotyping of Small Bowel Adenocarcinoma Active, not recruiting NCT02976090

Search NIH Clinical Center for Small Intestine Adenocarcinoma

Genetic Tests for Small Intestine Adenocarcinoma

Anatomical Context for Small Intestine Adenocarcinoma

MalaCards organs/tissues related to Small Intestine Adenocarcinoma:

40
Small Intestine, Colon, Liver, Appendix, Skin, T Cells, Lung

Publications for Small Intestine Adenocarcinoma

Articles related to Small Intestine Adenocarcinoma:

(show top 50) (show all 105)
# Title Authors PMID Year
1
Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma. 61
31685233 2020
2
Prognostic Significance of Stromal and Intraepithelial Tumor-Infiltrating Lymphocytes in Small Intestinal Adenocarcinoma. 61
31576398 2020
3
Detection of the Bacteroides fragilis toxin gene in sheep with and without small intestinal adenocarcinoma. 61
31378159 2019
4
Insurance status is related to overall survival in patients with small intestine adenocarcinoma: A population-based study. 61
31548047 2019
5
Celiac disease: a comprehensive current review. 61
31331324 2019
6
Assessment of the external validity of the AJCC 8th staging system for small intestinal adenocarcinoma: a time to reconsider the role of tumor location? 61
31183191 2019
7
DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. 61
30381262 2019
8
Retrospective study of survival time and prognostic factors for dogs with small intestinal adenocarcinoma treated by tumor excision with or without adjuvant chemotherapy. 61
30605388 2019
9
Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. 61
30375264 2018
10
[A Case of Intussusception in the Jejunum Due to Small Intestinal Adenocarcinoma]. 61
30237385 2018
11
Influence of marital status on small intestinal adenocarcinoma survival: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. 61
30532589 2018
12
Pancreatic non-functioning neuroendocrine tumor: a new entity genetically related to Lynch syndrome. 61
29184699 2017
13
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma? 61
28821192 2017
14
Metastatic intestinal adenocarcinoma to a lymph node involved by follicular lymphoma: The importance of looking beyond the apparent. 61
28476376 2017
15
Lynch syndrome-related small intestinal adenocarcinomas. 61
28206961 2017
16
Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas. 61
27169755 2016
17
[A Case of Ileocecal Intussusception Due to Small Intestinal Adenocarcinoma]. 61
28133155 2016
18
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. 61
26892442 2016
19
[A Case of Long-Term Survival in a Patient with Small Intestinal Adenocarcinoma with Peritoneal Dissemination]. 61
26809539 2016
20
Insulin-Like Growth Factor II mRNA-Binding Protein 3 (IMP3) as a Useful Immunohistochemical Marker for the Diagnosis of Adenocarcinoma of Small Intestine. 61
26855452 2015
21
[A Case of Small Bowel Cancer Treated with Laparoscopic Surgery]. 61
26805147 2015
22
Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma. 61
25710579 2015
23
[Four Cases of Primary Small Intestinal Cancer]. 61
26805145 2015
24
SMALL INTESTINAL ADENOCARCINOMA WITH CARCINOMATOSIS IN A SWIFT FOX (VULPES VELOX). 61
26352968 2015
25
Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. 61
25930983 2015
26
Lifestyle factors and small intestine adenocarcinoma risk: A systematic review and meta-analysis. 61
25736860 2015
27
Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine. 61
25759539 2015
28
Small bowel imaging in celiac disease. 61
25925931 2015
29
[A case of long-term survival of small intestinal adenocarcinoma treated by resection and chemotherapy]. 61
25731553 2014
30
Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. 61
24603585 2014
31
Notch3 signaling is associated with MUC5AC expression and favorable prognosis in patients with small intestinal adenocarcinomas. 61
24810798 2014
32
Recovering a stuck capsule … and discovering a rare small-intestinal adenocarcinoma. 61
24679662 2014
33
[A case report of primary adenocarcinoma of the small intestine with peritoneal dissemination treated with multidisciplinary therapy]. 61
25129097 2014
34
S100A4 expression is a prognostic indicator in small intestine adenocarcinoma. 61
24062356 2014
35
Coexistence of granulomatous enteric inflammation and neoplasia in an adult sheep. 61
23456963 2013
36
Molecular alterations of EGFR in small intestinal adenocarcinoma. 61
23644682 2013
37
Epithelial-mesenchymal transition phenotype is associated with patient survival in small intestinal adenocarcinoma. 61
24018801 2013
38
Small intestinal adenocarcinoma: rarely considered, often missed? 61
23412393 2013
39
Loss of S100A14 expression is associated with the progression of adenocarcinomas of the small intestine. 61
23038644 2013
40
Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology. 61
24240591 2013
41
Genome-wide gene expression profile of jejunal pouch mucosa as a gastric substitute. 61
22281974 2012
42
[A case of primary adenocarcinoma of small intestine responding to XELOX chemotherapy and leading to a partial metabolic response]. 61
22584343 2012
43
[Expression of Bcl-w protein in human small intestinal adenocarcinoma and effect of Bcl-w siRNA on apoptosis in intestinal adenocarcinoma HuTu-80 cells]. 61
22780970 2012
44
Small bowel adenocarcinoma complicating coeliac disease: a report of three cases and the literature review. 61
23243535 2012
45
Coeliac disease in endocrine diseases of autoimmune origin. 61
22744631 2012
46
High susceptibility to zymbal gland and intestinal carcinogenesis in diabetic Otsuka long-evans Tokushima Fatty rats. 61
22319230 2011
47
[A case report of multiple adenocarcinoma in small intestine after total gastrectomy by Roux-en-Y re-construction]. 61
22202278 2011
48
Surgical versus non-surgical treatment of feline small intestinal adenocarcinoma and the influence of metastasis on long-term survival in 18 cats (2000-2007). 61
22467965 2011
49
Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI, and CIMP. 61
21297586 2011
50
Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. 61
21088150 2010

Variations for Small Intestine Adenocarcinoma

Cosmic variations for Small Intestine Adenocarcinoma:

9 (show top 50) (show all 63667)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88261999 ZRSR2 small intestine,duodenum,carcinoma,adenocarcinoma c.611G>A p.S204N 23:15815730-15815730 24
2 COSM149332692 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.1691C>T p.A564V 16:72958455-72958455 24
3 COSM149265665 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.8576C>T p.T2859M 16:72794106-72794106 24
4 COSM91382445 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.35C>T p.P12L 11:32435311-32435311 24
5 COSM91384162 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.742G>T p.D248Y 11:32428524-32428524 24
6 COSM85193879 U2AF1 small intestine,duodenum,carcinoma,adenocarcinoma c.692C>T p.S231L 21:43093133-43093133 24
7 COSM87029034 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 24
8 COSM87035637 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 24
9 COSM87910722 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.764T>G p.I255S 17:7674199-7674199 24
10 COSM88214070 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.1052A>G p.K351R 17:7670657-7670657 24
11 COSM95881577 TGFBR2 small intestine,jejunum,carcinoma,adenocarcinoma c.1352C>T p.A451V 3:30674127-30674127 24
12 COSM135127211 TGFBR1 small intestine,duodenum,carcinoma,adenocarcinoma c.1136C>A p.T379K 9:99144882-99144882 24
13 COSM133362486 TET2 small intestine,duodenum,carcinoma,adenocarcinoma c.1124A>G p.E375G 4:105235066-105235066 24
14 COSM96854676 TENT5C small intestine,jejunum,carcinoma,adenocarcinoma c.839A>G p.D280G 1:117623707-117623707 24
15 COSM92119395 SUZ12 small intestine,duodenum,carcinoma,adenocarcinoma c.1058C>A p.P353H 17:31988354-31988354 24
16 COSM90702438 STK11 small intestine,jejunum,carcinoma,adenocarcinoma c.719C>T p.S240L 19:1220702-1220702 24
17 COSM90692741 STK11 small intestine,duodenum,carcinoma,adenocarcinoma c.580G>A p.D194N 19:1220488-1220488 24
18 COSM88446919 STAT3 small intestine,duodenum,carcinoma,adenocarcinoma c.635A>G p.Q212R 17:42337773-42337773 24
19 COSM86765978 STAG2 small intestine,duodenum,carcinoma,adenocarcinoma c.3018T>G p.F1006L 23:124083514-124083514 24
20 COSM93989109 SRC small intestine,duodenum,carcinoma,adenocarcinoma c.1460C>T p.P487L 20:37403228-37403228 24
21 COSM99811711 SPEN small intestine,duodenum,carcinoma,adenocarcinoma c.617G>A p.R206H 1:15876414-15876414 24
22 COSM99817072 SPEN small intestine,duodenum,carcinoma,adenocarcinoma c.4586G>A p.R1529H 1:15930826-15930826 24
23 COSM88094779 SOX9 small intestine,duodenum,carcinoma,adenocarcinoma c.242T>C p.L81P 17:72121633-72121633 24
24 COSM84674599 SMO small intestine,duodenum,carcinoma,adenocarcinoma c.1571C>T p.A524V 7:129210467-129210467 24
25 COSM89655095 SMARCA4 small intestine,duodenum,carcinoma,adenocarcinoma c.2647G>T p.G883C 19:11021755-11021755 24
26 COSM91386108 SMAD4 small intestine,jejunum,carcinoma,adenocarcinoma c.1157G>T p.G386V 18:51067036-51067036 24
27 COSM91381918 SMAD4 small intestine,duodenum,carcinoma,adenocarcinoma c.1612G>A p.E538K 18:51078420-51078420 24
28 COSM91075705 SMAD3 small intestine,duodenum,carcinoma,adenocarcinoma c.772G>A p.D258N 15:67181354-67181354 24
29 COSM91075523 SMAD3 small intestine,duodenum,carcinoma,adenocarcinoma c.1027T>G p.F343V 15:67187382-67187382 24
30 COSM88340746 SMAD2 small intestine,duodenum,carcinoma,adenocarcinoma c.938T>C p.L313S 18:47848534-47848534 24
31 COSM88343804 SMAD2 small intestine,duodenum,carcinoma,adenocarcinoma c.1298G>A p.S433N 18:47841933-47841933 24
32 COSM92477893 SH2B3 small intestine,duodenum,carcinoma,adenocarcinoma c.616G>A p.A206T 12:111418761-111418761 24
33 COSM89629666 SF3B1 small intestine,jejunum,carcinoma,adenocarcinoma c.1226C>A p.P409Q 2:197408011-197408011 24
34 COSM88232879 RPTOR small intestine,duodenum,carcinoma,adenocarcinoma c.3104C>T p.T1035M 17:80945745-80945745 24
35 COSM88235706 RPTOR small intestine,duodenum,carcinoma,adenocarcinoma c.2875T>C p.F959L 17:80925436-80925436 24
36 COSM93209816 RPS6KA4 small intestine,duodenum,carcinoma,adenocarcinoma c.1355G>A p.R452H 11:64368724-64368724 24
37 COSM93211056 RPS6KA4 small intestine,jejunum,carcinoma,adenocarcinoma c.806C>T p.A269V 11:64361902-64361902 24
38 COSM93849209 ROS1 small intestine,duodenum,carcinoma,adenocarcinoma c.1289G>A p.G430D 6:117389820-117389820 24
39 COSM103194883 RHOA small intestine,duodenum,carcinoma,adenocarcinoma c.77G>A p.S26N 3:49375513-49375513 24
40 COSM86691927 REL small intestine,duodenum,carcinoma,adenocarcinoma c.323G>A p.R108Q 2:60901012-60901012 24
41 COSM144751875 RECQL4 small intestine,duodenum,carcinoma,adenocarcinoma c.1649C>T p.A550V 8:144514497-144514497 24
42 COSM85615141 RAF1 small intestine,jejunum,carcinoma,adenocarcinoma c.770C>T p.S257L 3:12604200-12604200 24
43 COSM85615128 RAF1 small intestine,jejunum,carcinoma,adenocarcinoma c.776C>T p.S259F 3:12604194-12604194 24
44 COSM96919619 RAD54L small intestine,duodenum,carcinoma,adenocarcinoma c.1181G>A p.R394Q 1:46272477-46272477 24
45 COSM100085588 RAD50 small intestine,duodenum,carcinoma,adenocarcinoma c.3836G>A p.R1279H 5:132642261-132642261 24
46 COSM84609043 RAD21 small intestine,duodenum,carcinoma,adenocarcinoma c.1642G>A p.D548N 8:116849008-116849008 24
47 COSM97007554 PTPRT small intestine,duodenum,carcinoma,adenocarcinoma c.4291A>G p.T1431A 20:42081920-42081920 24
48 COSM139869371 PTPRS small intestine,jejunum,carcinoma,adenocarcinoma c.5482G>A p.A1828T 19:5210474-5210474 24
49 COSM139869389 PTPRS small intestine,jejunum,carcinoma,adenocarcinoma c.2698A>G p.T900A 19:5223094-5223094 24
50 COSM139869403 PTPRS small intestine,jejunum,carcinoma,adenocarcinoma c.341G>T p.G114V 19:5273480-5273480 24

Copy number variations for Small Intestine Adenocarcinoma from CNVD:

7 (show all 22)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13776 1 1 39600000 Copy number LCK Small bowel adenocarcinoma
2 13777 1 1 39600000 Copy number MDS2 Small bowel adenocarcinoma
3 13778 1 1 39600000 Copy number PAX7 Small bowel adenocarcinoma
4 13779 1 1 39600000 Copy number PRDM16 Small bowel adenocarcinoma
5 13780 1 1 39600000 Copy number RPL22 Small bowel adenocarcinoma
6 13781 1 1 39600000 Copy number SDHB Small bowel adenocarcinoma
7 76578 13 32900000 93800000 Copy number LCP1 Small bowel adenocarcinoma
8 76579 13 32900000 93800000 Copy number LHFP Small bowel adenocarcinoma
9 76580 13 32900000 93800000 Copy number RB1 Small bowel adenocarcinoma
10 106872 17 1 6800000 Copy number USP6 Small bowel adenocarcinoma
11 180663 4 10900000 191273063 Copy number CHIC2 Small bowel adenocarcinoma
12 180664 4 10900000 191273063 Copy number FBXW7 Small bowel adenocarcinoma
13 180665 4 10900000 191273063 Copy number FIP1L1 Small bowel adenocarcinoma
14 180666 4 10900000 191273063 Copy number IL2 Small bowel adenocarcinoma
15 180667 4 10900000 191273063 Copy number KIT Small bowel adenocarcinoma
16 180668 4 10900000 191273063 Copy number PDGFRA Small bowel adenocarcinoma
17 180669 4 10900000 191273063 Copy number PHOX2B Small bowel adenocarcinoma
18 180670 4 10900000 191273063 Copy number RAP1GDS1 Small bowel adenocarcinoma
19 244962 9 1 51800000 Copy number FANCG Small bowel adenocarcinoma
20 244963 9 1 51800000 Copy number JAK2 Small bowel adenocarcinoma
21 244964 9 1 51800000 Copy number MLLT3 Small bowel adenocarcinoma
22 244965 9 1 51800000 Copy number PAX5 Small bowel adenocarcinoma

Expression for Small Intestine Adenocarcinoma

Search GEO for disease gene expression data for Small Intestine Adenocarcinoma.

Pathways for Small Intestine Adenocarcinoma

Pathways related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 MSH6 MSH2 MLH1 KRAS HRAS
2
Show member pathways
12.55 SMAD4 MSH6 MSH2 MLH1 KRAS HRAS
3 12.46 SMAD4 MSH6 MSH2 MLH1 KRAS HRAS
4 12.25 USP10 MSH6 MSH2 MLH1
5 11.9 SMAD4 KRAS HRAS
6 11.89 SMAD4 MSH6 MSH2 KRAS
7
Show member pathways
11.87 SMAD4 KRAS HRAS
8 11.86 SMAD4 KRAS HRAS
9 11.83 PMS2 MSH2 MLH1
10 11.76 SMAD4 KRAS HRAS
11 11.67 SMAD4 KRAS HRAS
12 11.57 SMAD4 MSH6 MSH2 MLH1 KRAS
13 11.47 MSH6 MSH2 MLH1
14
Show member pathways
11.43 PMS2 MSH6 MSH2 MLH1
15 11.02 SMAD4 KRAS HRAS
16 10.95 KRAS HRAS
17 10.93 KRAS HRAS
18 10.87 KRAS HRAS
19 10.62 KRAS HRAS
20 10.39 PMS2 MSH6 MSH2 MLH1

GO Terms for Small Intestine Adenocarcinoma

Cellular components related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex GO:0032389 9.16 PMS2 MLH1
2 MutSalpha complex GO:0032301 8.96 MSH6 MSH2
3 mismatch repair complex GO:0032300 8.92 PMS2 MSH6 MSH2 MLH1

Biological processes related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.89 USP10 PMS2 MSH6 MSH2 MLH1
2 DNA repair GO:0006281 9.77 USP10 PMS2 MSH6 MSH2 MLH1
3 negative regulation of neuron apoptotic process GO:0043524 9.75 MSH2 KRAS HRAS
4 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.71 MUC6 KRAS HRAS
5 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.58 MSH6 MSH2 MLH1
6 regulation of long-term neuronal synaptic plasticity GO:0048169 9.57 KRAS HRAS
7 determination of adult lifespan GO:0008340 9.56 MSH6 MSH2
8 negative regulation of DNA recombination GO:0045910 9.55 MSH6 MSH2
9 positive regulation of isotype switching to IgG isotypes GO:0048304 9.52 MSH2 MLH1
10 response to isolation stress GO:0035900 9.51 KRAS HRAS
11 positive regulation of helicase activity GO:0051096 9.48 MSH6 MSH2
12 positive regulation of isotype switching to IgA isotypes GO:0048298 9.46 MSH2 MLH1
13 mismatch repair GO:0006298 9.46 PMS2 MSH6 MSH2 MLH1
14 maintenance of DNA repeat elements GO:0043570 9.43 MSH6 MSH2
15 isotype switching GO:0045190 9.43 MSH6 MSH2 MLH1
16 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.32 MSH2 MLH1
17 somatic recombination of immunoglobulin gene segments GO:0016447 9.13 MSH6 MSH2 MLH1
18 somatic hypermutation of immunoglobulin genes GO:0016446 8.92 PMS2 MSH6 MSH2 MLH1

Molecular functions related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.8 SMAD4 MSH6 MSH2 MLH1
2 ATPase activity GO:0016887 9.73 PMS2 MSH6 MSH2 MLH1
3 single-stranded DNA binding GO:0003697 9.63 PMS2 MSH2 MLH1
4 four-way junction DNA binding GO:0000400 9.48 MSH6 MSH2
5 MutSalpha complex binding GO:0032407 9.4 PMS2 MLH1
6 MutLalpha complex binding GO:0032405 9.37 MSH6 MSH2
7 oxidized purine DNA binding GO:0032357 9.32 MSH6 MSH2
8 single guanine insertion binding GO:0032142 9.26 MSH6 MSH2
9 single thymine insertion binding GO:0032143 9.16 MSH6 MSH2
10 guanine/thymine mispair binding GO:0032137 9.13 MSH6 MSH2 MLH1
11 mismatched DNA binding GO:0030983 8.92 PMS2 MSH6 MSH2 MLH1

Sources for Small Intestine Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....